ArticleMetabolic brain disease2025
Dexmedetomidine alleviates ferroptosis caused by traumatic brain injury via the NRF2/HO-1/GPX4 pathway.
Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lycopene ameliorates intestinal barrier dysfunction following traumatic brain injury by inhibiting pyroptosis.Scientific reports · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Emerging evidence suggests that TBI triggers ferroptosis, and dexmedetomidine (Dex) has a neuroprotective effect. This study aimed to explore the underlying mechanism of function of Dex in ferroptosisi after TBI. TBI model was established using the modified Feeney's weight drop injury method. Our experiment included the assessment of lesion volume by hematoxylin and eosin (HE) staining, the evaluation of the expression levels of ferroptosis-related proteins NRF2, HO-1, GPX4, FPN1, and TRFC by Western blotting (WB), the morphological changes via transmission electron microscopy (TEM), the increase in reactive oxygen species (ROS) through the measurement of malondialdehyde (MDA), the expression of HO-1 and GPX4 in the hippocampal tissues by immunofluorescence staining (IF), the behavioral assay by the Morris water maze (MWM) test and the open field test (OFT). Dex could alleviate the cognitive impairment in TBI mice and reduce ferroptosis after TBI. Dex could promote the nuclear translocation of NRF2 and enhance the expression of downstream HO-1, xCT, and GPX4, thereby inhibiting ferroptosis of neuronal cells. In addition, ML385 inhibited the expression of NRF2 and then reversed the neuroprotective effect of Dex. Dex alleviates ferroptosis and oxidative stress responses after TBI in mice through the NRF2/HO-1/GPX4 pathway, thus relieving the cognitive impairment in mice after TBI.
Indexed as
Identifiers
41191138What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.